#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Frisius

Verifiedinfo

The Netherlands Henri Dunantweg 2, 8934 AD Heerenveen, The Netherlands

53 trials recruiting
Acute myeloid leukaemia · Non-small cell lung cancer · Arteriosclerosis
Adults and children

About Specializations

Frisius in Heerenveen, The Netherlands specialises in clinical trials of conditions such as Acute myeloid leukaemia, Non-small cell lung cancer, Arteriosclerosis, Rectal cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Ophthalmology

The medical center is at the forefront of ophthalmology, focusing on innovative treatments for visual impairments. The center's research is particularly concentrated on addressing myopia in children, a growing concern worldwide.

Progressive Myopia Management
Visual Health in Pediatrics
Advanced Optical Treatments

By exploring the efficacy of various atropine concentrations, the center aims to enhance therapeutic strategies and improve patient outcomes in pediatric ophthalmology.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Henri Dunantweg 28934 AD HeerenveenThe Netherlands

Open in maps ↗

Recruiting now: 53 trials
Conditions studied: 97
Partner status: Verified

More sites in Heerenveen The Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

118 clinical trials

Non-small cell lung cancer stage I

Recruiting

Investigational

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Mrna-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Registered drug

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Arteriosclerosis

Recruiting

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Arteriosclerosis

Recruiting

Investigational

Study on the Effects of Obicetrapib and Ezetimibe on Coronary Plaque in Patients with Atherosclerotic Cardiovascular Disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ezetimibe
Sponsor:NewAmsterdam Pharma B.V.

Contact Research Centre

Acute myocardial infarction

Recruiting

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Selatogrel
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Atrial fibrillation

Recruiting

Investigational

Phase 3 Study of Etripamil Nasal Spray Compared with Placebo in Patients with Atrial Fibrillation and Rapid Ventricular Rate

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Etripamil
Sponsor:Milestone Pharmaceuticals Inc.

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Azd5004
Sponsor:AstraZeneca AB

Contact Research Centre

Polymyalgia rheumatica

Recruiting

Registered drug

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Acute myocardial infarction

Recruiting

Registered drugNo placebo

A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adenosine

Contact Research Centre

Chronic kidney disease+1

Recruiting

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Investigational

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:BLEXIMENIB
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.